ClavystBio’s Post

Dealmaking has hit biopharma front and center this year. 2024 is off to a great start with all the M&A and BD deal announcements leading up to the J.P. Morgan Healthcare Conference. With all the trials and tribulations biotech founders go through, M&A shines as the bright light at the end of the tunnel. Of course the announcements are the tip of the iceberg. A milestone achieved after months of engagement to find the right fit and the right partner.   If you have been following the space or looking for a recap, here is a list of deals announced so far this month. Here's to hoping for many more successful M&A exits this year!   #biotech #biopharma #dealmaking #jpm2024

#Partnerships with external investors like Tesi are crucial for BC Platforms' growth and internationalization. 🚀 #data #drugdevelopment #healthcare #precisionmedicine #healthtech #healthtechinnovation

In the fickle world of venture-backed biotech, the dual-track process is picking up steam. Explore an IPO, but also consider an M&A exit. Or, go the triple-track route: raise a crossover and prepare for a Wall Street debut while simultaneously building rapport with biopharma companies for a shot at an acquisition. “This is still a market where companies need to, in our view, explore any and all avenues to make sure that their product or their candidates can progress through the clinic as efficiently and quickly as possible and hopefully get into patients,” said Kevin Eisele. Companies like EyeBio, Escient, ProfoundBio and Mariana Oncology were likely IPO stories later this year, but were bought out first. Private biotechs are having their moment in the world of M&A. “There probably have to be more positive data readouts for some of the public stories to become of interest to big pharma again, but there’s plenty of high-quality private companies now for big pharma to look at that are clinical-stage, have generated positive clinical data and are also hot therapeutic areas,” said Daniel Parisotto, PhD. More below from my interviews with Kevin, Daniel, Jonathan Norris and Rachael Bushey, plus some insight from leaders at recent dual-trackers Carmot Therapeutics and HI-Bio. #biotech #pharma #biopharma #manda #mergersandacquisitions #dualtrack #ipo #nasdaq

French biotech: disappointing post-IPO performance. Over the period between January 2012 and February 2024, the analysis of the performance of French biotechs is disastrous, with only Medincell having a share price higher than that of its IPO. There are many reasons for this, with many clinical and regulatory failures confirming the binary nature of this industry. The problem is that the likelihood of seeing the light at the end of the tunnel is low for many companies. Is the peak negative sentiment is behind or ahead of us?

LianBio announces its closure, delisting from Nasdaq, and plans to return $528 million to shareholders via a special cash dividend of $4.80 per share. This decision follows asset sales to Bristol Myers Squibb and Johnson & Johnson and a strategic review aiming to maximize shareholder returns in a challenging biotech market. Key Points: 🔷 Closure and workforce reduction to focus on maximizing shareholder returns. 🔷 Special cash dividend and profits from asset divestments to be distributed. 🔷 Reflects strategic adaptability in response to the biotech industry's challenges. #Biotech #LianBio #ShareholderValue

The #PharmaConclave2024, hosted by Norton Rose Fulbright, KNAV US, and #Practus, brought together leading voices in the #PharmaceuticalSector to discuss the booming M&A landscape. As "patent cliffs" push large-cap companies to fill pipeline gaps, M&A activity has reached billions in deal value, with #Pfizer's $43B acquisition of #Seagen and #Merck’s $11B acquisition of #PrometheusBiosciences leading the way. Backed by $171B in cash reserves, the industry is focusing on #CNS and cardiometabolic diseases, which now account for 21% and 9% of deal value shares, respectively. The Conclave covered crucial insights on #MergersAndAcquisitions, #Tax, #Valuation, and #Accounting, setting the stage for #innovation and future growth in #biotech, and charting a course for the future of #finance and legal strategies in the evolving #pharma landscape. Shishir Lagu | Atul Deshmukh | Rajesh Khairajani | Navneet Sharma | Rajiv Khanna | Ravikanth Rao | Venkat S | Manju Rathnam | Laura DeFouw, CPA

Interesting observations from my colleague Jayshree Shah on how dealmakers and investors navigate the fast moving opportunities as AI and technology in general impact LSHC. Interpath Deal Advisory team are well placed to support companies and investors unlock and maximise value through the corporate lifecycle #mna #deals #lifescience #healthcaremna

Today on #BiotechHangout Daphne Zohar Tim Opler Ethan Perlstein Dawn Bell, PharmD Eric Schmidt discuss $GILD acquiring $CBAY for $4.3B, tracking 13F filings, quiet week on the IPO front & what $MGX reception means for IPO window, Ipsen FDA approval triggers $225M milestone payment to $MACK, plus data: $KALV Ph3 hits endpoints & CSL’s Ph3 trial ends, $ALY’s changes to its HELIOIS-B Ph3 study of vutrisiran, $LIAN shutting down & the continued sanctions against China biotechs, plus offerings: $LRMR, $SANA, $CRSP, $PRME, private financings: BioAge Labs $170M Series D & Latigo’s $135M Series A, & more: https://lnkd.in/e2PupHZx

📹In this video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead

In seeking investor interest, companies in the life sciences arena can find that being more focused instead of more diverse may be appealing.   Thank you PharmaVoice for speaking with me about the recent and steady pickup in M&A activity in the pharma industry. Read more below. #LifeSciences #M&A #Pharma